MedTrace Logo

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

NCT01996267 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 437

Last updated 2024-03-29

No results posted yet for this study

Summary

This study compares two schedules of upfront chemotherapy in HER positive breast cancer.

Conditions

Interventions

DRUG

PTC+Pertuzumab

Cycle repeated every 21 days

DRUG

FEC-T+Pertuzumab

Cycle is repeated every 21 days

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Borstkanker Onderzoek Groep

    collaborator NETWORK

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Gabe S Sonke, MD · Antoni van Leeuwenhoek, Amsterdam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2018-12-31
Completion
2030-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01996267 on ClinicalTrials.gov